Latest / The Integrative Clinician by BridgeWell / BridgeWell Briefs #6: LDN and Weight Loss: Don't Borrow the Evidence

Transcript

BridgeWell Briefs #6: LDN and Weight Loss: Don't Borrow the Evidence · The Integrative Clinician by BridgeWell

• 0:00
  Low-dose naltrexone is showing up everywhere in integrative medicine.
• 0:05
  Chronic pain, autoimmune conditions, inflammation, and increasingly in weight management.
• 0:11
  So when a patient asks you about low-dose naltrexone for weight loss, what do you say?
• 0:20
  Because there is an important distinction here.
• 0:24
  Naltrexone is part of an FDA-approved weight management medication when it is combined with bupropion.
• 0:33
  At specific doses, low-dose naltrexone by itself is something different.
• 0:39
  And if we blur those things together, we can accidentally make the evidence sound stronger than it is.
• 0:49
  This is the BridgeWell Brief, one focused clinical idea you can take into practice this week. Today we are talking about low-dose naltrexone and weight loss.
• 1:02
  Not whether low-dose naltrexone is good or bad. The better question is where does it actually fit? So let's start with the pharmacology. Naltrexone is an opiate receptor antagonist.
• 1:15
  At a standardized dose, it has established indications related to alcohol and opioid use disorders.
• 1:23
  In weight management, naltrexone is paired with bupropion in an FDA-approved extended release medication.
• 1:31
  That combination acts on the central pathways involved in appetite and reward.
• 1:37
  Low-dose naltrexone, usually discussed in integrative practice at low doses, far below standard naltrexone dosing, is an off-label strategy.
• 1:47
  There is an interest in low-dose naltrexone because of the proposed effects involving opioid signaling, immune modulation, and neuroinflammation.
• 1:58
  Those mechanisms are very interesting.
• 2:00
  But an interesting mechanism is not the same thing as evidence for clinically meaningful weight loss.
• 2:07
  Don't borrow evidence. This is the clinical pearl.
• 2:11
  Do not borrow evidence from one formulation, dose, or combination and apply it to another.
• 2:17
  If naltrexone plus bupropion produces weight loss, that does not prove that naltrexone low dose alone produces the same outcome.
• 2:26
  If low-dose naltrexone has emerging evidence in another condition that does not automatically make obesity an evidence-supported indication, that does not mean we can't use the therapies off-label.
• 2:39
  Nurse practitioners do that appropriately throughout medicine.
• 2:42
  It means we should be able to explain what is established, what is emerging, and what is mechanistic.
• 2:51
  Who is the patient?
• 2:52
  Before I think about weight management medications, I want to understand the phenotype.
• 2:59
  Is this primarily increased hunger, food noise, or reward-driven eating, insulin resistance or sleep deprivation, or menopause-related body composition changes?
• 3:08
  Another would be a medication promoting weight gain, untreated sleep apnea, loss of muscle mass, emotional eating, or is there another medical contributor we have not identified?
• 3:21
  Obesity is not one physiology, and one of the strengths of integrative medicine is that we do not have to treat it as if it were.
• 3:34
  Safety still comes first. Naltrexone blocks opioid receptors.
• 3:38
  That matters enormously if your patient uses opioid analgesics, has opioid dependence, may need opioid pain management, or has other contraindications or precautions.
• 3:49
  It is necessary to do medication reconciliation here.
• 3:53
  It is also important to get informed consent from a patient at all times, especially with off-label use.
• 4:03
  Patients should understand why we are considering it, what evidence exists for the intended use, what alternatives exist, what we are monitoring, and what outcome would tell us whether continuing makes sense or not? Where I think low-dose naltrexone fits.
• 4:23
  For weight loss alone, I would not present low-dose naltrexone as an equivalent to the FDA-approved obesity medication.
• 4:31
  The evidence is just not there.
• 4:34
  Could there be selected patients in whom an integrative clinician considers low-dose naltrexone for another appropriate clinical reason and observes changes in appetite and weight?
• 4:46
  Possibly. Could future research define a clearer metabolic role? Absolutely.
• 4:51
  But right now our language should match the evidence.
• 4:55
  We're not saying that this is an anti-integrative medicine, and we're also not saying that this is an excellent integrative medicine.
• 5:05
  So your Monday challenge, this week, choose one off-label therapy you use or are considering using.
• 5:13
  Ask yourself three questions. What evidence supports the exact drug at this dose and for what indication?
• 5:21
  Am I relying on mechanisms, clinical experience, or outcome data?
• 5:25
  Have I explained that distinction clearly to my patient?
• 5:30
  That simple exercise can dramatically improve informed clinical decision making.
• 5:35
  Inside BridgeWell Integrative Education, we teach nurse practitioners how to evaluate therapies exactly like this.
• 5:41
  What is the mechanism? What is the evidence? What is the safety, patient selection, and clinical context?
• 5:49
  Because becoming an integrative clinician is not about collecting unconventional treatments.
• 5:54
  It is about knowing how to use every tool more thoughtfully.
• 5:59
  If you want to build this kind of clinical reasoning, take a look at BridgeWell Integrative Education.
• 6:06
  And if this brief helped you think differently about low-dose naltrexone, share it with another nurse practitioner.
• 6:14
  Until next time, remember off label does not mean inappropriate.
• 6:18
  It means the responsibility for clear clinical reasoning becomes even more important. I'm Dr.
• 6:24
  Sheri Erwin, and this is Integrative Clinician by BridgeWell.